Troubling Findings in Study of GLP-1 Compounders

A secret shopper study found that 92% of weight-loss clinics and medical spas continue offering compounded semaglutide and 87% offer compounded tirzepatide despite FDA shortages ending, with over half adding unapproved ingredients like B vitamins and some operating from unlicensed or disciplined facilities with documented sterile compounding violations.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.